A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE3

מצבים רפואיים

Heart Failure

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • CON-10004 Fairhope, AL Investigational Site, Fairhope, Alabama, United States

  • CON-10075 El Centro, CA Investigational Site, El Centro, California, United States

  • CON-10024 Sacramento, CA Investigational Site, Sacramento, California, United States

  • CON-10022 Atlanta, GA Investigational Site, Atlanta, Georgia, United States

  • CON-10030 Baton Rouge, LA Investigational Site, Baton Rouge, Louisiana, United States

  • CON-10002 Kansas City, MO Investigative Site, Kansas City, Missouri, United States

    Contact: Study coordinator (Marc Bonaca)
  • CON-10045 Amarillo, TX Investigational Site, Amarillo, Texas, United States

  • CON-10015 Austin, TX Investigational Site, Austin, Texas, United States

  • CON-21003 Goiania, Goias Investigational Site, Goiânia, Goiás, Brazil

  • CON-21007 Joinville, Santa Catarina Investigational Site, Joinville, Santa Catarina, Brazil

  • CON-21004 Braganca Paulista, Sao Paulo Investigational Site, Bragança Paulista, São Paulo, Brazil

  • CON-21049 Sao Paulo, Sao Paulo Investigational Site, São Paulo, São Paulo, Brazil

  • CON-11012 Surry, BC Investigational Site, Surrey, British Columbia, Canada

  • CON-11007 North York, ON Investigational Site, North York, Ontario, Canada

  • CON-11005 Sherbrooke, QC Investigational Site, Sherbrooke, Quebec, Canada